Targeting Netrin-1: A Promising Approach to Inhibit EMT and Tumor Growth in Endometrial Cancer
Researchers have discovered that pharmacological targeting of netrin-1, a protein involved in tumor progression and metastasis, can inhibit epithelial-mesenchymal transition (EMT) in cancer. EMT is a process that allows cancer cells to acquire invasive and migratory properties, contributing to tumor metastasis. Netrin-1 has been found to promote EMT and is associated with poor prognosis in various types of cancer. By interfering with netrin-1, it may be possible to inhibit EMT and potentially limit cancer progression and metastasis.